It depends on the histological characteristics of the primary tumor, previous treatments and their tolerance, the site of metastatic lesions, the time to relapse and on predictive factors of treatment response (such as hormone-receptor expression or HER2 status) [35,36]. This evidence concerns the gene NR4A1 and neoplasm.